PUBLICATION
Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca2+ uptake and suppress cardiac arrhythmogenesis
- Authors
- Sander, P., Feng, M., Schweitzer, M.K., Wilting, F., Gutenthaler, S.M., Arduino, D.M., Fischbach, S., Dreizehnter, L., Moretti, A., Gudermann, T., Perocchi, F., Schredelseker, J.
- ID
- ZDB-PUB-210722-3
- Date
- 2021
- Source
- British journal of pharmacology 178(22): 4518-4532 (Journal)
- Registered Authors
- Schredelseker, Johann
- Keywords
- Anti-arrhythmic, Arrhythmia, CPVT, MCU, MiCUps, Mitochondria
- MeSH Terms
-
- Ezetimibe/metabolism
- Calcium/metabolism
- Ryanodine Receptor Calcium Release Channel/metabolism
- Calcium Signaling
- Pharmaceutical Preparations*/metabolism
- PubMed
- 34287836 Full text @ Br. J. Pharmacol.
Abstract
Treatment of cardiac arrhythmia remains challenging due to severe side effects of common anti-arrhythmic drugs. We previously demonstrated that mitochondrial Ca2+ uptake in cardiomyocytes represents a promising new candidate structure for safer drug therapy. However, druggable agonists of mitochondrial Ca2+ uptake suitable for preclinical and clinical studies are still missing. Here, we screened 727 compounds with a history of use in human clinical trials for their potential to enhance mitochondrial Ca2+ uptake. As a primary screening platform we used a previously validated permeabilized HeLa cell-based assay and identified three candidates. To reassess these hits in a cardiac system we tested them in cultured cardiomyocytes and found that two compounds, the FDA and EMA approved drugs ezetimibe and disulfiram, were effective in stimulating SR-mitochondria Ca2+ transfer at nanomolar concentrations, which is significantly lower compared to the previously described mitochondrial Ca2+ uptake enhancers (MiCUps) efsevin, a gating modifier of the voltage-dependent anion channel 2, and kaempferol, an agonist of the mitochondrial Ca2+ uniporter. Evaluation of their efficacy in translational models revealed that both substances significantly suppressed arrhythmogenesis in an in vivo zebrafish Ca2+ overload model and suppressed arrhythmogenic signals in both, freshly isolated ventricular cardiomyocytes of a mouse model for catecholaminergic polymorphic ventricular tachycardia (CPVT) and induced pluripotent stem cell derived cardiomyocytes from a CPVT patient. Taken together we identified ezetimibe and disulfiram as novel MiCUPs and efficient suppressors of arrhythmogenesis and as such as promising candidates for future preclinical and clinical studies.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping